New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer | Eli Lilly and Company
Eli Lilly presented data at ESMO 2026 showing promising results for olomorasib, an investigational treatment for KRAS G12C-mutant non-small cell lung cancer (NSCLC). The data showed durable efficacy in combination with immunotherapy, with or without chemotherapy, across PD-L1 expression levels. Olomorasib is not yet approved but has received Breakthrough Therapy designation from the FDA. The ongoing Phase 3 SUNRAY-01 study is evaluating olomorasib in first-line KRAS G12C-mutant NSCLC.
How this was made
The 30-second read
Why it matters
The presented data provide the first robust efficacy signals for olomorasib in the first‑line setting, potentially expanding Lilly's oncology pipeline.
Market read
New trial data could drive short‑term price appreciation for LLY and influence valuation of competing KRAS programs.
What to watch
The data are from early‑stage trials; efficacy in broader populations remains unproven.
Background
Eli Lilly's olomorasib is a next‑generation KRAS G12C inhibitor with Breakthrough Therapy designations. KRAS G12C NSCLC lacks approved first‑line targeted options.
Ticker impact
Lilly presented new first‑line olomorasib trial data at ESMO showing durable responses and safety in KRAS G12C NSCLC.
likely upside as market prices in potential future approvals and market share gains.
Data are first‑time disclosure, show strong efficacy and manageable safety, and support ongoing Phase 3 SUNRAY trials.
Market effects
strengthens the KRAS inhibitor segment and may pressure peers developing similar agents.
U.S. biotech sector could see modest gains on the back of the news.
global oncology investors may re‑price KRAS‑targeted pipelines.
Counterpoint
If safety concerns emerge in larger Phase 3 cohorts, the early optimism could reverse.
Key entities
- companyEli Lilly and Company
Developer of olomorasib, a KRAS G12C inhibitor.
